Table 1.
Patient Characteristics (n = 313).
| Age, median (range) | 59 years (27–90) |
| Histology | |
| Ductal | 271 (86.58%) |
| Lobular | 25 (7.99%) |
| Other | 17 (5.43%) |
| pT | |
| pT1 | 138 (44%) |
| pT2 | 135 (43.1%) |
| pT3 | 23 (7.3%) |
| pT4 | 17 (5.6%) |
| pN | |
| pN0 | 140 (44.73%) |
| >pN0 | 173 (55.27%) |
| LVI | |
| Yes | 96 (30.67%) |
| No | 217 (69.33%) |
| Grade | |
| 1 | 44 (14.06%) |
| 2 | 163 (52.08%) |
| 3 | 106 (33.86%) |
| Hormone receptor | |
| ER (+) and/or PgR (+) | 252 (80.5%) |
| ER (-) and PgR (-) | 61 (19.5%) |
| HER2 | |
| Pos | 74 (23.6%) |
| Neg | 239 (76.4%) |
| Ki67 | |
| Pos | 160 (51.1%) |
| Neg | 153 (48.9%) |
| CDC25A | |
| Median percentage of positive nuclei (range) | 19 (0–84) |
| Pos | 156 (49.8%) |
| Neg | 157 (50.2%) |
| Chemotherapy | |
| Yes | 179 (57.19%) |
| No | 97 (30.99%) |
| N/A | 37 (11.82%) |
| Hormone therapy | |
| Yes | 225 (71.89%) |
| No | 74 (23.64%) |
| N/A | 14 (4.47%) |
| Follow up, median (range) | 8 years (0–13) |
LVI indicates lymphovascular invasion; ER, estrogen receptor; PgR, progesterone receptor; ER cutoff = 10; PgR cutoff = 10; Ki67 cutoff = 25.